The latest price target for Barinthus Biotherapeutics (NASDAQ:BRNS) was reported by HC Wainwright & Co. on October 1, 2024. The analyst firm set a price target for $5.00 expecting BRNS to rise to within 12 months (a possible 293.70% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Barinthus Biotherapeutics (NASDAQ:BRNS) was provided by HC Wainwright & Co., and Barinthus Biotherapeutics reiterated their buy rating.

There is no last upgrade for Barinthus Biotherapeutics

There is no last downgrade for Barinthus Biotherapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Barinthus Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Barinthus Biotherapeutics was filed on October 1, 2024 so you should expect the next rating to be made available sometime around October 1, 2025.

While ratings are subjective and will change, the latest Barinthus Biotherapeutics (BRNS) rating was a reiterated with a price target of $5.00 to $5.00. The current price Barinthus Biotherapeutics (BRNS) is trading at is $1.27, which is out of the analyst’s predicted range.